MYndspan and BIOS Health Join Forces to Revolutionize Consumer Neuroscience
In a groundbreaking collaboration, MYndspan, a front-runner in the field of consumer brain health technology, has teamed up with BIOS Health, a pioneer in real-time neural data analysis. This partnership aims to broaden the reach and influence of precision neuroscience, enabling individuals to take charge of their neural health. By integrating MYndspan's cutting-edge Magnetoencephalography (MEG) brain assessments with BIOS Health's sophisticated AI platform for analyzing neural data, the two companies are on the verge of making advanced neural insights widely available. Until now, many of these technologies were mostly confined to research labs and specialized clinics.
Just as DNA sequencing transformed the landscape of precision medicine, the innovative, AI-assisted analysis of brain signals has the potential to reshape our understanding of brain function and lead us into an era of personalized medicine. MYndspan's approach focuses on non-invasive MEG scans that provide real-time insights into brain activity. This technology is heralded as the most advanced method for recording and analyzing brain functions, offering unique insights that can significantly enhance our understanding of various neurological conditions.
On the other hand, BIOS Health has developed a revolutionary infrastructure that utilizes real-time neural biomarkers to personalize treatment dosages for neuromodulation devices. This dual focus on precision and personalization is not just beneficial; it's essential for future advancements in brain health.
Caitlin Baltzer, the Co-Founder and CEO of MYndspan, commented on the agreement by stating, "This collaboration is more than just a partnership. It represents a crucial step towards rethinking how we assess, understand, and ultimately improve brain health. We aim to transform not only consumer access to brain health insights but also how clinicians diagnose and treat neurological issues."
Emil Hewage, CEO of BIOS Health, echoed this sentiment, noting that MYndspan's consumer-centric MEG technology perfectly complements their cutting-edge data framework. He asserted that their partnership would expedite the production and implementation of precision brain health tools, allowing healthcare professionals to make swifter and more informed decisions. This, in turn, will empower people to take charge of their mental well-being.
A recent study published in Imaging Neuroscience highlights MYndspan's ability to pinpoint markers associated with both healthy and accelerated brain aging, providing a foundation for advances in understanding neurodegenerative disorders. The ongoing research and findings will soon translate into practical applications that hold promise for individual consumers as well as entire healthcare systems.
In uniting innovative consumer technology with clinical-grade machine learning approaches, MYndspan and BIOS Health are committed to transforming the landscape of brain health for millions worldwide.
About MYndspan: MYndspan is on a mission to enhance access to preventive brain health care and is the first company globally to introduce non-invasive MEG technology to consumers. This revolutionary approach makes MEG, a technique generally reserved for specialized clinics, available for everyday users. The technology is built upon over 35 years of research and more than 300 peer-reviewed studies. Their goal is to create an essential preventive measure for better brain health, facilitating early detection of conditions like neurodegeneration and functional abnormalities triggered by invisible injuries, such as concussions and PTSD.
Website: www.myndspan.com
About BIOS Health: BIOS Health boasts an AI-driven data platform that customizes neuromodulation dosages in real time, with the potential to revolutionize treatments across various therapy areas, including cardiac, respiratory, and neurological disorders. The company was co-founded by researchers from Cambridge University, and its board includes prominent figures from institutions like Oxford University, underscoring its scientific rigor.
Website: www.bios.health
Just as DNA sequencing transformed the landscape of precision medicine, the innovative, AI-assisted analysis of brain signals has the potential to reshape our understanding of brain function and lead us into an era of personalized medicine. MYndspan's approach focuses on non-invasive MEG scans that provide real-time insights into brain activity. This technology is heralded as the most advanced method for recording and analyzing brain functions, offering unique insights that can significantly enhance our understanding of various neurological conditions.
On the other hand, BIOS Health has developed a revolutionary infrastructure that utilizes real-time neural biomarkers to personalize treatment dosages for neuromodulation devices. This dual focus on precision and personalization is not just beneficial; it's essential for future advancements in brain health.
Caitlin Baltzer, the Co-Founder and CEO of MYndspan, commented on the agreement by stating, "This collaboration is more than just a partnership. It represents a crucial step towards rethinking how we assess, understand, and ultimately improve brain health. We aim to transform not only consumer access to brain health insights but also how clinicians diagnose and treat neurological issues."
Emil Hewage, CEO of BIOS Health, echoed this sentiment, noting that MYndspan's consumer-centric MEG technology perfectly complements their cutting-edge data framework. He asserted that their partnership would expedite the production and implementation of precision brain health tools, allowing healthcare professionals to make swifter and more informed decisions. This, in turn, will empower people to take charge of their mental well-being.
A recent study published in Imaging Neuroscience highlights MYndspan's ability to pinpoint markers associated with both healthy and accelerated brain aging, providing a foundation for advances in understanding neurodegenerative disorders. The ongoing research and findings will soon translate into practical applications that hold promise for individual consumers as well as entire healthcare systems.
In uniting innovative consumer technology with clinical-grade machine learning approaches, MYndspan and BIOS Health are committed to transforming the landscape of brain health for millions worldwide.
About MYndspan: MYndspan is on a mission to enhance access to preventive brain health care and is the first company globally to introduce non-invasive MEG technology to consumers. This revolutionary approach makes MEG, a technique generally reserved for specialized clinics, available for everyday users. The technology is built upon over 35 years of research and more than 300 peer-reviewed studies. Their goal is to create an essential preventive measure for better brain health, facilitating early detection of conditions like neurodegeneration and functional abnormalities triggered by invisible injuries, such as concussions and PTSD.
Website: www.myndspan.com
About BIOS Health: BIOS Health boasts an AI-driven data platform that customizes neuromodulation dosages in real time, with the potential to revolutionize treatments across various therapy areas, including cardiac, respiratory, and neurological disorders. The company was co-founded by researchers from Cambridge University, and its board includes prominent figures from institutions like Oxford University, underscoring its scientific rigor.
Website: www.bios.health
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.